USPTO serial 79270317
CARTIHEAL THE FUTURE OF JOINT REPAIR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 4, 2020
- Examiner
- VALLILLO, MELISSA C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with CARTIHEAL THE FUTURE OF JOINT REPAIR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $1,275
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John L. Strand
John L. Strand Wolf, Greenfield & Sacks, P.C.600 Atlantic AvenueBoston, MA 02210United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for the treatment of genetic, cardiovascular, central nervous system, endocrine, gastrointestinal, hepatic, biliary, immunological, allergic, pulmonary, dermatological, infectious, inflammatory, menopausal, nutritional, metabolic, diabetes, autoimmune, musculoskeletal, bone, connective tissue, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, erectile dysfunction, sexual dysfunction, gynecology, obstetric, pediatric, hematologic, oncological, fungal and viral diseases and disorders; veterinary preparations and substances for the treatment of genetic, cardiovascular, central nervous system, endocrine, gastrointestinal, hepatic, biliary, immunological, allergic, pulmonary, dermatological, infectious, inflammatory, menopausal, nutritional, metabolic, diabetes, autoimmune, musculoskeletal, bone, connective tissue, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, erectile dysfunction, sexual dysfunction, gynecology, obstetric, pediatric, hematologic, oncological, fungal and viral diseases and disorders; medicines for the treatment of genetic, cardiovascular, central nervous system, endocrine, gastrointestinal, hepatic, biliary, immunological, allergic, pulmonary, dermatological, infectious, inflammatory, menopausal, nutritional, metabolic, diabetes, autoimmune, musculoskeletal, bone, connective tissue, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, erectile dysfunction, sexual dysfunction, gynecology, obstetric, pediatric, hematologic, oncological, fungal and viral diseases and disorders; pharmaceutical preparations and medicines for preventing transplant rejection; chemical, biochemical and biological substances for medical and veterinary purposes, namely, body and cartilage implants comprising living tissue; sanitary preparations for medical purposes; food for babies; dietary supplements for humans and animals; nutritional supplements, vitamins, mineral supplements; medical plasters, materials for dressings, namely, gauze; medical adhesive tape, namely, dissolvable strips to stop bleeding from minor cuts and grazes; material for stopping teeth, dental wax; disinfectants for hygienic purposes; chemical preparations for pharmaceutical purposes, namely, for genetic, cardiovascular, central nervous system, endocrine, gastrointestinal, hepatic, biliary, immunological, allergic, pulmonary, dermatological, infectious, inflammatory, menopausal, nutritional, metabolic, diabetes, autoimmune, musculoskeletal, bone, connective tissue, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, erectile dysfunction, sexual dysfunction, gynecology, obstetric, pediatric, hematologic, oncological, fungal and viral diseases and disorders; diagnostic preparations for medical use; diagnostic reagents for medicinal use; preparations for destroying vermin; fungicides, herbicides | ACTIVE | — |
| 010 | Surgical apparatus and instruments; medical, dental and veterinary apparatus and instruments for use in transplantation; artificial limbs, eyes and teeth; orthopedic articles, namely, braces, joint implants made from artificial materials, shoe inserts, wrist, neck, back, ankle, knee and elbow supports and splints; bone, joint, ankle, knee, elbow, leg and hand prostheses; surgical implants comprised of artificial materials; medical implants, namely, bone and cartilage implants comprised of artificial materials; spinal implants comprised of artificial materials; suture materials; replacement parts for the aforementioned goods | ACTIVE | — |
| 035 | Retail and wholesale services, namely, retail and wholesale stores featuring pharmaceutical preparations, medicines, medical, surgical and dental apparatus and instruments, nutritional supplements, vitamins, mineral supplements; advertising and business management services; business management; providing office functions; import agencies; sales promotion services; business consulting services; business information services; public relations services; electronic commerce services, namely, providing information about products via telecommunication networks for advertising and sales purposes; procuring of contracts for purchase of advertising space; rental of advertising space; direct mail advertising; business networking; arranging of business introductions; conducting of exhibitions for business purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CARTIHEAL (2009) LTD.
- Other trademarks owned by CARTIHEAL (2009) LTD.
- Other trademarks owned by CARTIHEAL (2009) LTD.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Similar marks named CARTIHEAL THE FUTURE OF JOINT REPAIR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 4, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Mar 30, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 27, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 27, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Feb 27, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 27, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 27, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 27, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 20, 2022 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Aug 21, 2022 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Dec 12, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 25, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 25, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 25, 2020 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Nov 4, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 1, 2020 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Aug 4, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 19, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 19, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 29, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 14, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 14, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 14, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 14, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 14, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 10, 2020 | DMCC | DATA MODIFICATION COMPLETED | — |
| Apr 9, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 9, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 9, 2020 | ALIE | ASSIGNED TO LIE | — |
| Apr 1, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 14, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 23, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 22, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 2, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 2, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 1, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 29, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 29, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 24, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |